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The last decade has brought a comprehensive change in our view of cardiac remodeling
processes under both physiological and pathological conditions, and cardiac stem cells
have become important new players in the general mainframe of cardiac homeostasis.
Different types of cardiac stem cells show different capacities for differentiation into
the three major cardiac lineages: myocytes, endothelial cells and smooth muscle cells.
Physiologically, cardiac stem cells contribute to cardiac homeostasis through continual
cellular turnover. Pathologically, these cells exhibit a high level of proliferative activity in
an apparent attempt to repair acute cardiac injury, indicating that these cells possess
(albeit limited) regenerative potential. In addition to cardiac stem cells, mesenchymal
stem cells represent another multipotent cell population in the heart; these cells are
located in regions near pericytes and exhibit regenerative, angiogenic, antiapoptotic, and
immunosuppressive properties. The discovery of these resident cardiac stem cells was
followed by a number of experimental studies in animal models of cardiomyopathies, in
which cardiac stem cells were tested as a therapeutic option to overcome the limited
transdifferentiating potential of hematopoietic or mesenchymal stem cells derived from
bone marrow. The promising results of these studies prompted clinical studies of the
role of these cells, which have demonstrated the safety and practicability of cellular
therapies for the treatment of heart disease. However, questions remain regarding this
new therapeutic approach. Thus, the aim of the present review was to discuss the
multitude of different cardiac stem cells that have been identified, their possible functional
roles in the cardiac regenerative process, and their potential therapeutic uses in treating
cardiac diseases.
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The increase in the average human lifespan has been accompanied by an increased incidence of
chronic diseases (Torella et al., 2007). These chronic non-communicable diseases are the result of
a number of risk factors and are characterized by a prolonged natural course and the potential for
developmental disabilities. These diseases are not only prevalent but also aggressive, and they dom-
inate death statistics. According to theWorld Health Organization (WHO), cardiovascular diseases
(including heart attack and stroke) represent the largest number of deaths from non-communicable
diseases, 17.5 million people annually, followed by cancer (8.2 million) and respiratory diseases
(4 million)1.
1Available at: http://www.who.int/mediacentre/factsheets/fs355/en/ Acessed January 10, 2015.
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Heart failure is a particularly lethal, disabling, and
expensive-to-treat disorder that has reached epidemic lev-
els in industrialized nations (Bolli et al., 2011). Even with
significant advances in the treatment of coronary artery disease
and the management of acute myocardial infarction in humans,
this pathological event remains the leading cause of mortality in
developed countries (Gnecchi et al., 2008; Wang et al., 2014) and
is highly associated with morbidity because a large population
of infarct survivors will develop cardiac failure (Hellermann
et al., 2002). In addition to a significant level of morbidity, and
direct cost of treatments by physicians and other professionals,
hospital services, medications, home health care, and other
medical durables, the health-related expenditures associated
with cardiovascular diseases include indirect costs, such as lost
productivity resulting from morbidity and premature mortality
(Go et al., 2013). If all forms of major cardiovascular disease
were eliminated, human life expectancy might increase by
approximately 7 years (Go et al., 2014).
Given the striking impact of these diseases on mortality rates,
most prognostic models of heart failure focus onmortality, which
is easily determined and highly relevant; however, other clini-
cal outcomes also rank high in importance to individual patients
(Allen et al., 2012). Because a large fraction of patients with
advanced heart failure report poor quality of life and significant
emotional distress due to debilitating symptoms such as breath-
lessness, fatigue, and sleeping difficulties (Hallas et al., 2011),
quality of life is a significant outcome to be considered. When
advanced heart failure patients discuss their goals, quality of life is
an important issue because how well they will live is as important
as how long they will live (Allen et al., 2012).
Depending on the specific condition(s), therapeutic options
for patients living with heart diseases include lifestyle changes,
drugs to prevent disease advancement, angioplasty, bypass
surgery, pacemakers, left ventricular assist devices and, finally,
heart transplantation (Smith et al., 2008a). This final treatment is
unavailable to many patients because of a lack of donor organs or
the presence of comorbidities that make the procedure inviable.
Given the deleterious consequences of heart disease, new
therapeutic approaches are needed because the progression of
heart disease involves loss of the myocardium, scar forma-
tion and remodeling of remaining cardiac tissue (Smith et al.,
2008a). Invasive treatments and optimized medical therapies are
increasingly successful in addressing the acute manifestations
of coronary artery diseases. However, although these treatment
strategies often extend the lives of patients, theymay not return to
healthy lives (Torella et al., 2007). As the incidence of heart failure
increases exponentially, novel therapies using cellular treatments
or regenerative strategies are being sought (Chong et al., 2011).
In particular, patients have high expectations for cellular therapy
(Lovell and Mathur, 2011).
Cardiac Physiological Homeostasis—the
Heart as a Dynamic Organ
Fortunately, the last decade has witnessed the dawn of a new era
in myocardial biology (Ellison et al., 2012), with the initiation of
many promising studies of treatment strategies based on cellular
therapies for heart patients. Until recently, the heart was consid-
ered a static and post-mitotic organ lacking regenerative capacity
(Beltrami et al., 2003; Chan et al., 2009; Lovell and Mathur, 2011;
Ellison et al., 2012), i.e., the number of cardiomyocytes in an indi-
vidual was established at birth (Barile et al., 2007; Kajstura et al.,
2010b), and cardiomyocyte hypertrophy was considered the only
cellular adaptive response of the heart (Lovell andMathur, 2011).
In this context, it was assumed that the age of a cardiomyocyte
would correspond to the age of the organism (Torella et al., 2007;
Kajstura et al., 2010a) and that a cardiomyocyte, lacking the abil-
ity to divide, could only increase its size or die, and the process
of cellular survival was ensured by the continual replacement of
intracellular organelles.
Careful, reproducible, and widely reported experiments have
overthrown this static-organ theory. Convincing evidence sug-
gests that cardiomyocytes are renewed throughout life, with con-
tinual cellular turnover in the mammalian heart, which also has
an intrinsic regenerative capacity (Barile et al., 2007). However,
the precise rate of cardiomyocyte turnover remains unclear (Elli-
son et al., 2013). This rate is difficult to study in humans because,
in most cases, the necessary methodology involves the use of
analogous nucleotide markers (Bergmann et al., 2010). Nuclear
bomb testing during the Cold War resulted in integration of 14C
into cellular DNA, making it possible to determine the age of car-
diomyocytes in humans based on analysis of the natural radioac-
tive isotype of carbon to estimate their turnover rate (Bergmann
et al., 2010). These studies suggested an annual turnover rate of
0.2–2%; however, a clear negative correlation between the cellular
renewal rate and age was observed (Bergmann et al., 2010).
In addition, the source of cardiomyocyte renewal throughout
life is unknown (Chong et al., 2011). At least two different origins
of these cells must be considered when examining the stimuli that
regulate the renewal of cardiomyocytes. As early as, Anversa and
Kajstura (1998) proposed that preexisting cardiac cells can divide
both under physiological conditions and in response to car-
diac overload. Subsequent detailed in vitro studies, supported by
video microscopy, confirmed the mitotic capacity of cardiomy-
ocytes, particularly mononucleated cardiac myocytes, despite
their complex organization (Bersell et al., 2009). At baseline,
the mitotic capacity is quite limited, but a considerable propor-
tion of mitotic cardiomyocytes are observed in ischemic hearts
and, compared to normal hearts, infarcted hearts have 70 times
as many myocytes undergoing mitosis within the border zone
(Beltrami et al., 2001).
The second source of mitotic cardiac cells considers the role of
cardiac stem cells (CSCs). In 2003, the heart was shown to be reg-
ulated by its own pool of stem cells (Beltrami et al., 2003), which
established the role of these multipotent cells in regulating the
rate of cellular turnover and preserving organ homeostasis.
Cardiac Stem Cells
CSCs were first isolated by Beltrami et al. (2003) and character-
ized as a population of cells that were positive for the c-kit surface
receptor (Di Felice et al., 2009). In addition to the presence of this
receptor, CSCs exhibit clonogenic and self-renewal capacities and
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multipotentiality, allowing them to differentiate along the three
main cardiac lineages: myocytes, endothelial cells and smooth
muscle cells (Di Felice et al., 2009) (Figure 1).
In addition to c-kit, other specific phenotypic markers define
other “types” of CSCs, although some of these markers may be
co-expressed by some cells. CSCs of particular interest include (i)
c-kit+; (ii) side population cells; (iii) Sca-1+; (iv) Isl1+; and (v)
CSCs derived from cardiospheres (Chan et al., 2009). These CSCs
all exhibit properties consistent with “real stem cells,” including
the following: (i) a lack of complete differentiation; (ii) the ability
to divide without limitation; (iii) symmetrical division to gener-
ate two daughter stem cells to expand the stem cell compartment
of the heart, i.e., self-renewal, or even asymmetrical to generate
one daughter stem cell and a cell bound to a specific cellular
lineage (Urbanek et al., 2006; Kajstura et al., 2010b) that subse-
quently undergoes terminal cellular differentiation (Raff, 2003;
Leri et al., 2005).
c-Kit+ Cardiac Stem Cells
c-Kit+ CSCs are undifferentiated cells whose in vitro and in vivo
properties are essentially identical and indistinguishable between
species (Ferreira-Martins et al., 2012). c-Kit is a transmembrane
receptor for a tyrosine kinase factor, and its ligand–stem cell fac-
tor (SCF)–is an early hematopoietic growth factor (Chen et al.,
2013). c-Kit+ cells are the most widely studied CSCs. These
cells are one-tenth the size of cardiomyocytes and may express
cardiac-specific-lineage transcription factors such as Nkx2.5,
GATA4, and Mef2 (Beltrami et al., 2003; Barile et al., 2007).
Their transcriptional profile indicates that c-Kit+ cells are the
most primitive population present in the heart and may play a
role in early mesodermal development and stem-cell signaling
pathways (Dey et al., 2013). Because the c-Kit receptor is also
expressed by various differentiated adult cells, such as mast cells
(Fang et al., 2012), in addition to being positive for c-kit, CSCs
must also be negative for various cell-specific lineage markers
(e.g., c-Kit+Lin−).
c-Kit+Lin− CSCs are found in small clusters in the inter-
stices between well-differentiated myocytes, in which it is
possible to observe cells at several stages of early cardiac myo-
genic differentiation based on their expression of the charac-
teristic transcription factors, allowing one to infer that these
clusters represent myogenic precursors and progenitor cells
derived from the activation of more primitive stem cells
(Beltrami et al., 2003).
Human cardiac homeostasis is closely related to β-adrenergic
signaling throughout life, and an important study demonstrated
the existence of a direct relationship between the β-adrenergic
receptor system and c-Kit+ CSCs (Khan et al., 2013). c-Kit+
CSCs exhibit cardiac β2-adrenergic receptors at their mem-
branes; and the function assigned to them is to stimulate multi-
potent CSCs to proliferate via the ERK-Akt pathway (Khan et al.,
2013).
When isolated c-Kit+ cells are grown in suspension, they
form spheres containing hundreds of cells similar to the pseudo-
embryoid bodies formed by neural stem cells (neurospheres). By
FIGURE 1 | Functional properties of cardiac stem cells. Cardiac
stem cells are not differentiated cells and can divide without limitation.
During cellular division, these cells can divide through symmetrical
division to increase their numbers. Alternatively, these stem cells can
undergo asymmetrical cellular division to produce both a daughter stem
cell and a progenitor cell, the latter of which can differentiates along the
three major cardiac lineages: cardiomyocytes, endothelial cells or
smooth muscle cells.
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analogy, these spheres were called cardiospheres and represent
a population of multipotent cells with distinct characteristics
(Torella et al., 2007).
Cardiosphere-derived Stem Cells
Initially isolated by Messina et al. (2004), cardiosphere-derived
cells (CDCs) can differentiate intomyocytes, endothelial cells and
smooth muscle cells (Li et al., 2010). CDCs have been character-
ized as clonogenic cells, and they express markers of stem cells
and endothelial progenitor cells (Messina et al., 2004). Stem cells
derived from cardiospheres in a three-dimensional configuration
exhibit a higher rate of c-Kit expression and increased expres-
sion of Nanog and SOX2, two important stem-cell transcription
factors (Li et al., 2010).
A recent report investigating stem cell surfacemarkers showed
that CDCs are CD105+ stromal cells of intrinsic cardiac origin
that include a variable fraction of CD90 (Thy-1)-positive cells and
a small minority of c-kit+ cells, which have been argued to rep-
resent cardiac progenitors (Cheng et al., 2014). A clinical trial in
which CDCs were transplanted into infarcted areas revealed that
the c-kit+ cells in cardiospheres are not an important determi-
nant of the therapeutic efficacy of CDCs, whereas CD90+ cells
appear to undermine the overall benefit of CDC therapy (Cheng
et al., 2014). Thus, c-kit expression on CDCs may be irrelevant to
the therapeutic efficacy of this stem cell type. Moreover, the disso-
ciation of cardiospheres into single cells appears to decrease their
expression of extracellular matrix and adhesion molecules and
affect their resistance to oxidative stress, negating the improved
cellular engraftment and functional benefit of CDCs in vivo (Li
et al., 2010).
Sca-1+ Cardiac Stem Cells
Sca-1+ cells, which express the surface marker stem cell antigen
1, were initially isolated from mouse hearts by Oh et al. (2003)
andMatsuura et al. (2004), who demonstrated that these cells can
differentiate into distinct cell lines in vitro (Di Felice et al., 2009).
This differentiation ability is retained even after long-term prop-
agation in vitro (Wang et al., 2014). Sca-1 is a convenient marker
for stem-cell studies because it is expressed by stem/progenitor
cells and its expression is upregulated in a variety of murine can-
cer stem cells. Recent studies have identified Sca-1+ in various
tissues, such as the mammary gland (Welm et al., 2002), prostate
(Xin et al., 2005), dermis (Toma et al., 2005), skeletal muscle
(Gussoni et al., 1999), heart (Rosenblatt-velin et al., 2005), and
liver (Wulf et al., 2003). However, in all cases, it is unclear if the
Sca-1+ populations are tissue-specific precursor/stem cells or are
the hematopoietic, mesenchymal, or endothelial precursor/stem
cells associated with these tissues (Holmes and Stanford, 2007).
The Sca-1 marker is used to characterize CSCs only in associ-
ation with other specific markers to exclude differentiated cells
and cells of other lineages.
Cardiac Sca-1+ cells are capable of cardiac repair and have
high levels of telomerase. These cells have the ability to migrate
and home to areas of injured myocardium (Oh et al., 2003).
In vitro, they can be propagated for a long period without any
significant changes in marker expression (Wang et al., 2014).
Molecular identification studies have indicated that Sca-1+ cells
are more strongly correlated with cardiomyocytes compared to
c-Kit+ cells (Dey et al., 2013). Moreover, Sca-1+ cells obtained
from adult hearts express GATA4 and Csx/Nkx-2.5, suggesting
that they are committed to the cardiomyocyte lineage to some
degree (Matsuura et al., 2004).
Some Sca-1+ cells are committed to the cardiomyogenic
lineage before birth; subsequently, Sca1-derived cells play a sig-
nificant role by contributing continuously to cardiomyogene-
sis (Uchida et al., 2013). However, it appears that Sca1+ cells
are more responsive to inductive cues that promote differen-
tiation into cardiomyocytes in healthy compared to diseased
myocardium (Uchida et al., 2013), which might explain the lim-
ited but important contribution of Sca-1+ CSCs to the adult
myocardium. Recent findings partly corroborate this theory,
demonstrating the relevant role of endothelial cells in generating
cardiomyocyte progeny in the adult heart, with direct involve-
ment of cardiac Sca-1+ cells in this process (Fioret et al., 2014).
Lineage tracing experiments have revealed endothelial progeny
in perivascular areas, including Sca-1+ cardiac progenitor cells,
suggesting that a significant fraction of Sca1+ CSCs are descen-
dants of endothelial cells (Fioret et al., 2014). These Sca-1+ cells
proliferate, leave the coronary niche, and differentiate into car-
diomyocytes, which indicates that the coronary vessels serve as
an Sca-1 cell niche and further suggest that a negative impact on
this niche environment evoked by any type of insult to coronary
vessels could affect the proliferation and differentiation of CSCs
(Fioret et al., 2014).
Side-population Stem Cells
Another phenotypic class of CSCs is side population cells and
was initially discovered by Hierlihy et al. (2002) based on their
identification of cells sensitive to verapamil in the adult human
myocardium. These cells are characterized by their ability to
promote the eﬄux of metabolic markers, such as Hoechst dye,
due to high expression of membrane pumps and genes con-
ferring resistance to multiple drugs (Hierlihy et al., 2002; Mar-
tin et al., 2004). This eﬄux ability is due to their expression of
the Abcg2 protein, which belongs to the family of transporters
linked to the ATP cassette (ABC transporters), early during car-
diac development, which endows these cells with their charac-
teristic phenotype (Di Felice et al., 2009). Under pathological
conditions, human Abcg2 mRNA levels increase, suggesting the
possibility of the activation and proliferation of side popula-
tion cells in response to cardiac diseases in an attempt to pro-
mote the reparative potential (Smith et al., 2008b). Increased
numbers of cells expressing Abcg2 have also been detected in
the marginal zone of acute infarcted myocardium (Barile et al.,
2007).
When co-cultured with cardiomyocytes, side population
cells express markers of terminal differentiation and exhibit
the electrophysiological characteristics of differentiated cardiac
myocytes, including their response to β-adrenergic agonists (Bar-
ile et al., 2007). Under physiological conditions, side population
cells can be isolated only from the hearts of very youngmammals,
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and the number of these cells decreases rapidly during the first
weeks of life (Barile et al., 2007). Approximately 93% of side
population cells are also positive for Sca-1 (Oh et al., 2003).
Isl1+ Stem Cells
The characteristic marker of Isl1+ cells is the LIM-homeodomain
transcription factor Islet-1 (Laugwitz et al., 2005). Some of the
distribution features of these cells suggest that Isl1+ cells are
organ-specific progenitor cells remaining from the fetal progen-
itor population (Laugwitz et al., 2005). Murine or human Isl1+
cells derived from embryonic stem cells have been shown to give
rise to cardiomyocytes, which exhibit appropriate electrophysio-
logical properties, such as action potentials and Ca2+ transients
(Cagavi et al., 2014), as well as smooth muscle cells and endothe-
lial cells (Lui et al., 2013). Contrary to previous assumptions,
Isl1+ cells are not exclusively in an embryonic state because there
is a subpopulation of endogenous CSCs that persist through-
out life and co-express both c-kit and isl1 (Fuentes et al., 2013).
Because all progenitor cells expressing Isl1 also express c-kit but
not all c-kit+ cells express Isl1, Isl1+c-kit+ progenitor cells may
be a subpopulation of c-kit+ progenitors (Fuentes et al., 2013).
Comparisons of embryonic and adult Isl1+ cells have revealed
that their significantly different levels of proliferative and migra-
tory abilities are a consequence of age (Fuentes et al., 2013).
Cardiac progenitor cells derived from embryonic stem cells may
be a valid source for cell-based cardiac-repair therapies because
their use would address the age-related decline in cardiac pro-
genitor cell function; furthermore, the potential risk of teratoma
formation and genomic alterations attributed to embryonic cells
is minimal for Isl1+ cells because they are highly committed
cardiovascular cells (Cagavi et al., 2014).
Cardiac Mesenchymal Stem Cells
Another class of multipotent cells present in the heart are cardiac
mesenchymal stem cells (cMSCs), which have been referred to
in the literature as cardiac mesenchymal stem-like cells (Ryzhov
et al., 2014) and cardiac mesenchymal-like stromal cells (Vecellio
et al., 2012). MSCs were initially derived from the plastic-
adherent fraction of components of mononuclear cells isolated
by density-gradient centrifugation of bone marrow cells and cul-
turing on an adherent surface (Friedenstein et al., 1974). MSCs
have since been derived from many organs other than bone mar-
row (da Silva Meirelles et al., 2006) and were recently, identified
in the cardiac stroma (Chong et al., 2011).
The phenotypic characterization of this cell type is complex,
and there is not a specific marker or combination of markers
to identify MSCs (Javazon et al., 2004). In culture, the phe-
notype of MSCs is altered; the surface markers of freshly iso-
lated mesenchymal cells differ from those maintained in culture
for a long period (Eggenhofer et al., 2014). In addition to the
absence of a “phenotypic marker,” the characteristics of MSCs
differ depending on the species of origin (Javazon et al., 2004).
Therefore, MSCs are usually defined based on a combination of
physical, morphological, phenotypic, and functional properties
(Javazon et al., 2004; Le Blanc and Ringdén, 2005). The follow-
ingminimal criteria have been established for the identification of
MSCs: (i) adherence to plastic; (ii) adipogenic, chondrogenic, and
osteogenic differentiation capacities; (iii) expression of CD73,
CD90 and CD105 and the absence of surface markers such as
CD45, CD34, CD11b and CD14, CD79α or CD19 and HLA-
DR.; and (iv) ability to generate colony-forming unit fibroblasts
(CFU-Fs) (Dominici et al., 2006; Gambini et al., 2011).
In contrast to other stem cells present in the heart, MSCs
lose their multipotentiality with passage in culture and enter
senescence (Javazon et al., 2004), which means that the growth
potential of these cells is limited. Bulk cultures of freshly iso-
lated cardiac CFU-Fs grow exponentially for approximately 40
passages before entering senescence (Chong et al., 2011). Despite
this limitation, these cells have important regenerative, angio-
genic, antiapoptotic, and immunosuppressive properties (Nora
et al., 2012).
MSCs can suppress monocyte differentiation into den-
dritic cells and down-regulate the expression of costimulatory
molecules by mature dendritic cells, thereby decreasing their
secretion of IL-12 and suppressing T-cell activation and prolifer-
ation (Jiang et al., 2005). In addition, MSCs regulate the function
of macrophages by polarizing these cells preferentially to the M2
anti-inflammatory phenotype and consequently creating an envi-
ronment favorable for accommodating therapeutic MSCs (Cho
et al., 2014).
In the heart, cardiac MSCs are negative for c-Kit and posi-
tive for both pericyte (CD146+) and fibroblast markers (vimentin
and human fibroblast surface antigen) and exhibit features sim-
ilar to those of syngeneic MSCs extracted from bone marrow,
such as comparable morphology and the expression of mes-
enchymal antigens (CD105, CD73, CD29, and CD44) (Vecellio
et al., 2012). However, comparison of bone marrow and cardiac
CFU-Fs revealed distinct lineage signatures, indicating that they
arise from different progenitor beds during development (Chong
et al., 2011). Thus, a preferable differentiation capacity appears to
develop depending on the source of the MSCs (Kern et al., 2006).
Thus, given the criteria of each CSC “type” and the vari-
ety of primitive cells existing in the heart, it is unlikely that
these CSCs perform the same biological functions (Dey et al.,
2013). It remains to be elucidated whether phenotypically differ-
ent CSCs are different types of undifferentiated cells originating
from different precursors (Wang et al., 2014) or only represent
different developmental stages of the same generic CSC (Torella
et al., 2007; Ellison et al., 2013), with only modest variations in
phenotype (Ferreira-Martins et al., 2012).
Organization and Distribution of Resident
Stem Cells in the Heart
In the heart, the CSCs are organized in niches that are prefer-
entially allocated in the atrium and ventricular apex, areas that
are protected because they are exposed to low levels of hemo-
dynamic stress (Leri, 2009). These niches are connected by sup-
porting cells, such as fibroblasts and myocytes, highlighting the
importance of connexins and cadherins, which play roles in
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the formation of gap junctions and adherens junctions at the
interfaces of these different cell types (Barile et al., 2007; Ferreira-
Martins et al., 2012). These cardiac niches create the micro-
environment necessary for the long-term residence, survival, and
growth of CSCs (Urbanek et al., 2006), providing nutrition and
enabling them tomaintain tissue homeostasis (Barile et al., 2007).
The homeostasis of these niches is mediated by symmetric and
asymmetric mitosis, with a predominance of asymmetric mito-
sis, which ensures the protection of the pool of stem cells and
the production of lineage-committed cells (Urbanek et al., 2006;
Barile et al., 2007).
On the other hand, cardiac MSCs are located near pericytes
and are widely distributed in different organs in association with
vessel walls (da Silva Meirelles et al., 2006). In the heart, MSCs
occupy a perivascular, adventitial niche and may represent a pop-
ulation of progenitor cells that are able to maintain the integrity
of the matrix, stroma, and vessels of the heart and contribute
to the parenchyma, particularly in cases of injury and disease
(Chong et al., 2011).
Extracardiac Stem Cells in the Heart
Stem cells other than resident CSCs are found in the heart. Evi-
dence for the presence of mobile stem cells in the heart was
provided by human heart transplantation experiments in which
a significant number of Y-chromosome positive myocytes and
coronary vessels were observed in the transplanted heart when
the donor was female and the recipient was male (Quaini et al.,
2002). In this case, the male cells in the female heart suggested
the existence of mobile stem cells that were capable of dif-
ferentiating into cardiomyocytes, endothelial cells or vascular
smooth muscle cells (Beltrami et al., 2003). When the origin
and population dynamics of cardiac progenitor cells were inves-
tigated using a heterotopic mouse heart transplantation model,
cells that migrated to the heart after transplantation gradually
ceased expressing the hematopoietic markers CD45 and CD34
and began to express cardio-specific transcription factors such
as GATA-4 and Nkx2.5, hence acquiring a cardiac-cell pheno-
type (Li et al., 2007). Conditions other than organ transplantation
that have the potential to attract circulating stem cells and the
potential sources of these cells are being investigated.
Hematopoietic stem cells (HSCs) reside predominantly in the
bone marrow but can be found in the peripheral blood in low
numbers (Wright et al., 2001) and in the spleen, which is consid-
ered an active hematopoietic organ because it serves as a reser-
voir for hematopoietic stem cells for relatively immediate use
(Morita et al., 2011). Little is known about the physiological role
of these HSCs in normal adult tissue homeostasis (Zhang et al.,
2006), although it has been described that HSCs have the abil-
ity to acquire a cardiomyocyte phenotype (Orlic et al., 2001; Rota
et al., 2007).
The chemokine SDF-1α (stromal-derived factor-1) has a well-
described role in the subsequent migration and homing of stem
cells. SDF-1α belongs to the subfamily of chemokines that can
facilitate the transmigration of hematopoietic cells through the
endothelial cell barrier (Chen et al., 2013). In an infarction
model, the attraction exercised by SDF-1 is not homogeneous
for the different types of stem cells because more c-kit+ than
Sca-1+ cells were recruited, for example (Zhang et al., 2007).
This chemokine also participates in the recruitment of resident
CSCs in specific situations by binding to the CXCR4molecules of
these cells (Zakharova et al., 2010; Wang et al., 2012; Yan et al.,
2012; Chen et al., 2013; Ellison et al., 2013). The up-regulation
of CXCR4 expression increases the vascularization of the injured
myocardium, and the SDF-1/CXCR4 axis appears to be partic-
ularly important in the chemotaxis, homing, engraftment and
attachment of progenitor cells to the injured myocardium (Wang
et al., 2006b).
Hypoxic preconditioning increases the expression of CXCR4
in c-Kit+ cells, which indicates that this response is related to
the promotion of cellular survival achieved by activating the
SDF1-α/CXCR4 axis (Yan et al., 2012). Furthermore, the rapid
increase in chemokines/cytokines such as SDF-1α contributes to
the upregulation of MMP-9 (matrix-metalloproteinase 9) expres-
sion, which is involved in the recruitment of hematopoietic stem
cells (Heissig et al., 2002). Matrix metalloproteinases are a fam-
ily of endopeptidases that act as physiological regulators of the
extracellular matrix (Shah et al., 2011). For example, upon car-
diac injury, the activation of c-kit+ cells via anMMP-9 dependent
pathway is required to mobilize progenitor cells from bone mar-
row to home to the heart (Fazel et al., 2008). In an acute myocar-
dial infarction model, an increase in MMP-9 levels was observed,
which may represent an endogenous mechanism for the recruit-
ment of undifferentiated stem cells to the area of myocardial
injury (Shah et al., 2011).
It is not clear if the cells attracted to the injured heart due
to chemokine stimulus or stimulation by other factors released
by the remaining heart cells or, in the absence of injury, due to
the growth factors released by the heart are able to acquire a
differentiated cardiac-cell phenotype. Using parabiotic pairs of
animals, Wagers et al. (2002) observed that despite high levels of
cross hematopoietic grafting, under physiological and stable con-
ditions, multiple tissues showed no evidence of grafting of the
circulating hematopoietic stem cells on non-hematopoietic tissue
(Wagers et al., 2002). These findings suggested that hematopoi-
etic cells do not develop into non-hematopoietic cells; however,
the authors could not rule out atypical properties arising in
response to severe injury or selective pressure (Wagers et al.,
2002). Their theory was that at steady state, tissue regenera-
tion appears to derive predominantly from progenitor cells res-
ident in the tissue rather than from circulating cells (Wagers
et al., 2002). Subsequently, to investigate cellular migration in
response to pathological stimulus, Balsam et al. (2004) performed
a left anterior descending coronary-artery ligation immediately
after parabiosis surgery in mice. After 8 weeks, large num-
bers of GFP+ cells were observed surrounding the scar tissue;
however, these cells co-expressed CD45, some co-expressed cell
marker B (B220), a few co-expressed a T-cell marker (CD3),
and none expressed cardiac or smooth muscle markers (Bal-
sam et al., 2004). These results suggest that even after car-
diac injury, circulating cells do not regenerate myocardium.
However, the descending artery was ligated immediately after
the animals were joined, and circulatory chimerism was not
yet established, which may have led to an underestimation
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of the cells that migrated to the lesion foci (Aicher et al.,
2007).
In another model used to investigate stem-cell migration,
mice were subjected to irradiation, and bone marrow cells were
replaced by eGFP+ bone marrow cells. After cardiac injury, sev-
eral types of histological analysis revealed that no cardiac cells
with fluorescent-protein expression were present in the heart,
indicating that stem cells derived from the bone marrow do
not directly contribute to cardiomyocyte formation in injured
or uninjured hearts (Ellison et al., 2013). Thus, the currently
available evidence indicates that the resident or organ-specific
stem cells contribute to the maintenance of tissue homeostasis,
whereas the non-resident circulating stem cells that are attracted
to organs minimally contribute to this physiological process,
highlighting the restorative activities of these cells when attracted
to an organ by certain stimuli (Figure 2), which was first demon-
strated in 2002 via chimerism in a post-transplantation organ
(Laflamme, 2002; Quaini et al., 2002; Angelini et al., 2007).
Cardiac Stem Cells under Homeostatic or
Unstable Conditions
In addition to contributing to the maintenance of tissue home-
ostasis (Ferreira-Martins et al., 2012; Waring et al., 2014), CSCs
participate in reparative processes under pathological conditions
(Bailey et al., 2009; Ellison et al., 2013). However, extensive dam-
age cannot be completely reversed, i.e., the regenerative poten-
tial of stem cells in damaged tissues is limited (Bailey et al.,
2009; Chan et al., 2009; Hatzistergos et al., 2010). Therefore, mas-
sive degenerative events such as myocardial infarction cannot be
counteracted by resident CSCs (Smith et al., 2008b).
Under physiological conditions, the pool of resident c-kit+
CSCs present during early cardiac development were sug-
gested to be responsible for expanding the myocyte mass dur-
ing embryonic, fetal, and immediate postnatal development
(Ferreira-Martins et al., 2012). However, the results of a recent
study overturned this assumption, by demonstrating, using a very
elegant model and analyzing different stages of cardiac develop-
ment as well as the postnatal period, that the c-kit+ CSCs con-
tributed minimally to cardiomyocyte formation (van Berlo et al.,
2014). By contrast, these cells play a significant role in the ori-
gin of endothelial cells (van Berlo et al., 2014). Furthermore, the
physiological role of c-Kit+ CSCs includes paracrine activity. In
vitro experiments revealed an increased rate of cardiomyocyte
survival when c-Kit+ CSCs were co-cultured with adult rat car-
diomyocytes, and the secretion of growth factors, such as IGF-1
(insulin-like growth factor 1) and VEGF (vascular endothelial
growth factor), appeared to be responsible for the beneficial effect
(Miyamoto et al., 2010). In addition, with respect to cardiac repair
after heart injury, c-Kit+ CSCs can acquire a cardiomyocyte phe-
notype (Ellison et al., 2013), highlighting the different activities
of these multipotent cells under physiological and pathological
conditions.
Certain conditions can lead to functional impairment of CSCs.
In the pathological heart, the homeostatic control of stem cell
growth is defective, resulting in cellular senescence (Chimenti
et al., 2003; Urbanek et al., 2005) and apoptosis (Urbanek et al.,
2005). Thus, although the number of CSCs increases after an
ischemic cardiac event, the level of regeneration is not in the
expected range, which is at least partially attributable to the acqui-
sition of a senescent phenotype bymany CSCs in infarcted hearts.
These cells thus lose their regenerative capacity and become
non-cycling, non-differentiating cells (Urbanek et al., 2005).
Functional problems also occur in CSCs in chronic systemic
disease, and these changes have implications for the heart. Dia-
betes leads to decompensated myopathy, an etiology that is
poorly understood. Because the heart constantly renews itself, an
imbalance between cellular death and regeneration may occur
in diabetes, and this imbalance may be mediated by defects in
the growth and survival of c-Kit+ CSCs, which are massively
reduced in number, as well as reductions in telomere length
(Rota et al., 2006). The impairment in cardiac progenitor cell
function as a consequence of the enhanced oxidative stress that
occurs with this disease affects cellular turnover, resulting in an
excessive number of old, dying, and poorly contracting myocytes
and, ultimately, ventricular failure, which in turns may result
in the pathological manifestations of diabetic myopathy (Rota
et al., 2006).When diabetes is treated with antioxidants, the num-
bers and functional abilities of both progenitor cardiac cells and
mature cardiac cells are preserved, and a marked recovery of ven-
tricular function is observed (Delucchi et al., 2012), supporting
the theory that oxidative stress in diabetes leads to the loss of
CSCs.
The same damaging effects of oxidative stress appear to be
involved in the cardiac injury observed in subjects treated with
anti-tumor therapies. Anthracyclines are effective drugs for the
treatment of some neoplastic diseases (De Angelis et al., 2010),
but they have profound effects on the structure and function of
the heart, which over time causes cardiomyopathy that evolves
to congestive heart failure (Takemura and Fujiwara, 2007). The
cardiotoxicity of the anthracyclines is dose dependent, limiting
their aggressive use (De Angelis et al., 2010). In vitro studies
have demonstrated that anthracyclines promote oxidative stress
and the activation of p53, a protein that regulates the cell cycle,
thereby affecting the growth and survival of c-Kit+ CSCs. This
effect supports the theory that defects in progenitor cell func-
tion may condition the development of cardiac myopathy in vivo
(De Angelis et al., 2010; Prezioso et al., 2010). Thus, deleterious
cardiac effects with different causes may be due to targeting of
CSCs, emphasizing that injury to these cells that contribute to the
maintenance of cardiac homeostasis will have inevitable cardiac
consequences.
Chronological age is a major predictor of the presence of
biomarkers of human CSC senescence such as telomere short-
ening, attenuated telomerase activity, telomere dysfunction, and
the expression of p21Cip1 and p16INK4a, both of which are
senescence-associated proteins (Cesselli et al., 2011), raising
questions about the functional capacity of cells taken from
aging hearts and hearts in chronic failure. Comparative analy-
ses of CSCs isolated from transplanted hearts (both donor and
explanted hearts) have revealed that the clonogenic capacity of
CSCs in the heart in heart failure is three times lower than
that of cells from healthy hearts. By contrast, the differentiation
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FIGURE 2 | Schematic representation of the mechanisms through
which stem cells are involved in both cardiac homeostasis and in the
heart repair. In response to acute insult, the damaged myocardium elicits the
activation of cardiac and also extracardiac stem cells (represented by the
continuous dark blue arrows). The cardiac stem cells are activated in response
to growth factors, like VEGF (vascular endothelial growth factor) and
IGF-1(insulin-like growth factor 1), while extracardiac stem cells (schematically
represented by hematopoietic bone marrow cells) are chemo- attracted into
the injured sites through the axis SDF-1α/CXCR4 (stromal-derived
factor-1/receptor CXCR4). With the insult chronicity, the participation of
cardiac and extracardiac stem cells in the damaged heart is reduced, possibly
due to an unfavorable microenvironment to the action of these cells
(represented by the continuous dark green arrows). Considering the uninjured
heart, in a stable condition, the available information indicates that cardiac
homeostasis is ensured by an active role of cardiac stem cells (represented by
the continuous light blue arrow), with an unclear role of extracardiac stem cells
(represented by light blue dashed arrow). Seeing both acute, chronic and
stable conditions, in response to environmental stimuli, cardiac stem cells
differentiate into cardiomyocytes, endothelial cells or smooth muscle cells and
also, possibly, release soluble autocrine/paracrine factors that play roles in
both stem cells self-renewal and myocardial protection/neovascularization
respectively, while extra cardiac stem cells are involved in the beneficial
modulation of the microenvironment, since the capacity of them to acquire a
differentiated phenotype, crossing lineage boundaries, is questionable.
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potentials of CSCs from healthy and infarcted hearts were com-
parable and yielded similar proportions of myocytes, smooth
muscle cells, and endothelial cells, indicating the possibility of
autologous transplantation in individuals with heart failure (Ces-
selli et al., 2011). Thus, even in decompensated hearts, there is a
compartment of functionally competent CSCs that, despite lower
growth kinetics, retain the ability to expand and differentiate.
These characteristics are promising for the clinical application of
these cells (Cesselli et al., 2011).
MSCs are affected by aging and exhibit diminished expression
of Nanog, a transcription factor that retains MSCs in a primi-
tive state, as well as increased adipocytic potential (Cieslik et al.,
2011). Furthermore, fibroblasts derived from aged MSCs exhibit
reduced expression of transforming growth factor-β (TGF- β)
receptors, attenuated contractility and migratory ability (Cies-
lik et al., 2011), and decreased expression of α-SMA, an indica-
tor of poor maturation into myofibroblasts (Cieslik et al., 2013).
In addition, the fibroblasts derived from elderly MSCs exhibit
increased expression of type I collagen due to the elevation of
circulating plasma insulin levels with aging (Cieslik et al., 2013).
Future in vivo studies using pathological models treated with car-
diac MSCs isolated from animals of different ages could be able
to reveal possible differences in the functional abilities of aged
cells.
Cellular Therapy with Stem Cells as a
Treatment Option
A massive number of cardiomyocytes die after a heart attack,
and the basic concept for cellular therapy following myocardial
infarction must consider this large-scale cellular loss resulting in
heart failure (Lovell and Mathur, 2011). Therefore, treatments
based on stem cell transplantation aim to avoid the loss or failure
of cardiovascular function (Sánchez et al., 2010) and to rescue
the numbers of cardiomyocytes to ensure good cardiac perfor-
mance (Noseda and Schneider, 2010). It is important to repair
not only the cardiomyocytes but also the endothelial and smooth
muscle cells, which are crucial for developing a new network of
arteries to bring nutrients and oxygen to the cardiomyocytes and
restore organ function after heart damage. In the acute phase of
a myocardial infarction (MI), the goals of cellular therapy are
to prevent cardiomyocyte death, promote local neoangiogenesis,
improve myocardial perfusion, and reduce local inflammatory
responses (Takashima et al., 2013). Another major objective of an
ideal clinical intervention is to avoid scar formation or replace
scar tissue with functioning cardiac muscle tissue (Curtis and
Russell, 2010).
Orlic et al. (2001) demonstrated that c-Kit+Lin− bone-
marrow cells could regenerate the infarcted myocardium by
demonstrating that the newly formedmyocardium occupied 68%
of the infarcted portion of the ventricle 9 days after transplanting
the bone marrow cells. However, these results were not repro-
duced by other researchers, who consistently demonstrated that
hematopoietic stem cells did not readily acquire a cardiac phe-
notype (Balsam et al., 2004; Murry et al., 2004). This discrep-
ancy was attributed to the assays used to detect cardiomyogenic
differentiation, which was exclusively based on immunofluores-
cence staining and is thus difficult to use in tissues with high levels
of non-specific autofluorescence, as is typically encountered in
the infarcted heart (Murry et al., 2004).
However, despite the absence or extremely low rate of acquisi-
tion of a cardiac phenotype, experimental studies and, to a lesser
extent, clinical studies (Schächinger et al., 2006; Tendera et al.,
2009; Hare et al., 2012) have investigated the use of stem cells
derived from bone marrow in cases of cardiac injury. Optimistic
results have been reported, such as an acceleration of left ven-
tricular ejection fraction (LVEF) recovery after acute myocardial
infarction, although this was observed without a long-term ben-
efit on left ventricular systolic function measured at 18 months
after bone marrow cells transfer (Meyer et al., 2006). However, a
trend in favor of this cell therapy is defended, particularly consid-
ering patients with severely impaired LVEF at baseline (Tendera
et al., 2009). The favorable results arising from the transplan-
tation of bone marrow cells have been attributed to humoral
(Cho et al., 2007) and paracrine effects rather than the direct
regeneration of various cardiac cells through transdifferentiation
(Loffredo et al., 2011).
Importantly, bone marrow-derived stem cells are easy to
obtain in sufficient numbers for transplantation, which hastens
the transplantation process because it is not necessary to seed
these cells in culture to expand their number. However, because
the ability of this cell type to differentiate to replace dysfunctional
cardiac tissue is limited, other stem cells with this capability have
been sought. Thus, criteria for the ideal cell type for the promo-
tion of consistent improvements in the damaged myocardium
with a real potential to replace lost cells have been established.
These cells should be capable of differentiating into functional
cardiomyocytes and of forming new vessels (Sánchez et al., 2010),
indicating cardiac commitment, and they should be able to inte-
grate with the target tissue by developing gap junctions with host
cells without inducing immune reactions. Lastly, from a practical
standpoint, these cells should preferably exhibit some degree of
resistance to ischemia to avoid massive apoptosis during cellular
transfer (Gaetani et al., 2009).
Thus, among the types of stem cells studied to date, cardiac
progenitor/stem cells appear to represent an attractive option for
use in clinical trials because they are intrinsically more likely to
possess all of the characteristics required to repair the damaged
heart (Lovell and Mathur, 2011) and improve cardiac function
after myocardial injury (Torella et al., 2007).
Cellular Therapy with Cardiac Stem
Cells–Experimental Models
Initial studies of CSCs considered the potential for tropism to
the site of cardiac injury but demonstrated that all regenerat-
ing cells were located in the necrotic area and not the spared
myocardium, even though the cells were injected at the bor-
der between the ischemic and healthy myocardium (Beltrami
et al., 2003). The injured myocardium provides a milieu that
supports the homing, nesting, survival, and differentiation of
CSCs (Ellison et al., 2013). Furthermore, cardiac tropism is
Frontiers in Physiology | www.frontiersin.org 9 May 2015 | Volume 6 | Article 123
Leite et al. Multipotent stem cells in the heart
CXCR4-SDF-1 axis-dependent, and the enhanced expression
of SDF-1 in the surviving myocardium serves as a positive
chemotactic agent (Ellison et al., 2013), activating the lig-
ands of the CSCs themselves through auto/paracrine feedback
(Torella et al., 2007).
Therefore, the potential of CSCs as a convenient source for
autologous stem-cell therapy has been considered for clinical tri-
als of myocardial regeneration (Gaetani et al., 2009). One of the
main advantages of autologous transplantation is the elimination
of the potential for a potent immunological response against the
allograft in the host. However, CSCs are significantly more diffi-
cult to harvest and isolate than bone marrow-derived mononu-
clear cells (Lovell and Mathur, 2011). Furthermore, the number
of cells that can be obtained from an individual is quite small;
however, these cells can be expanded in culture (Gaetani et al.,
2009). Thus, it is feasible that cells isolated from very small frag-
ments of human myocardium and expanded many-fold in vitro
could reach numbers appropriate for in vivo transplantation in
patients while retaining their differentiation potential (Messina
et al., 2004).
Among the different stem cells types already described, c-kit+
CSCs as well as cells derived from cardiospheres have been more
frequently utilized in experimental and clinical studies because
they are cell populations with well-defined characteristics and
extraction and expansion methods. Moreover, compared to the
other adult stem cells in the heart, they appear to be in the most
primitive stage of differentiation.
Experimental models of myocardial infarction have demon-
strated satisfactory responses after the administration of CSCs,
such as an improvement of myocardial remodeling following
injury via a combination of a reduction in the cell death rate,
induction of endogenous repair mechanisms, and the contribu-
tion of new cells to the injured myocardium (Bailey et al., 2009).
The results suggested that c-Kit+ CSCs promote myocardial
regeneration, which contributes to the recovery of the structure
and function of the damaged heart (De Angelis et al., 2010).
Studies employing a model of diffuse myocardial damage
causing acute heart failure revealed that the extent of myocardial
injury is even more pronounced when endogenous c-Kit+ CSCs
are ablated from the adult myocardium (Ellison et al., 2013).
Following the administration of c-Kit+ CSCs, cardiac function
was restored through the regeneration of the lost cardiomy-
ocytes, smooth muscle cells, endothelial cells, and fibroblasts and
even through the maintenance of the stemness of the stem cells
(Ellison et al., 2013).
When cells derived from cardiospheres were administrated to
transgenic animals with dilated cardiomyopathy, anti-apoptotic,
anti-fibrotic and cardioproliferative effects were observed, as well
as a decrease in mortality (Aminzadeh et al., 2015). However, the
beneficial effects of administering these cells to treat pathological
processes were most pronounced when the cells were supplied
in the form of cardiospheres, thereby ensuring that a niche sim-
ilar to that self-developed through these stem-cell structures was
maintained (Li et al., 2010).
In an in vivo study in which Sca-1+ CSCs were transplanted in
a mouse cardiac-infarction model, significant angiogenesis was
observed in the peri-infarction regions, although with minimal
differentiation of the Sca-1+ cells into endothelial cells, contrary
to the substantial in vitro endothelial-cell differentiation capacity
of these cells (Wang et al., 2006a). These cells transdifferentiated
into cardiomyocytes more frequently, albeit the absolute num-
ber of newly differentiated cardiomyocytes was low and most
likely insufficient to make substantial direct contributions to
left ventricular structure, function, or bioenergetic character-
istics (Wang et al., 2006a). However, despite the low rate of
transdifferentiation of these cells, transplantation of Sca-1+ CSCs
attenuated the development of adverse structural, functional, and
energetic abnormalities associated with left ventricular remod-
eling post-myocardial infarction, likely due to paracrine effects
(Wang et al., 2006a).
When the effects of bone marrow-derived mesenchymal
stem cells were compared to those of mesenchymal stem cells
derived from the human heart following direct injection into the
myocardium of chronically infarcted rats, the cMSCs survived
longer in the tissue, better promoted angiogenesis via paracrine
mechanisms, and more efficiently differentiated into cardiomy-
ocytes than the MSCs derived from the bone marrow (Rossini
et al., 2011). In addition, combining these cells with other types
of stem cells appears to be important. In an animal model,
combining stromal cells derived from heart tissue with stem
cells derived from cardiospheres resulted in increased survival
of this cell group upon transplantation in the infarcted areas,
and the cardiac contractile function and extent of replacement
of the injured myocardium were optimized because this combi-
nation of cells promoted vascularization and cardiomyogenesis
(Zakharova et al., 2010).
Furthermore, because the paracrine action exerted by MSCs
can be attributed, at least in part, to the extracellular vesicles
released by MSCs (previously referred to as microvesicles or exo-
somes) (Bian et al., 2014), which have the capacity to change
the phenotype of injured cells through the horizontal trans-
fer of mRNA, microRNA and proteins, it appears that these
cells have the potential to be exploited as an alternative to stem
cell-based therapy in novel therapeutic approaches to repair
damaged tissues (Biancone et al., 2012). In vivo, the extracel-
lular microvesicles derived from bone marrow-derived MSCs
elicited neoangiogenesis in ischemic hearts and improved func-
tional recovery in an rat cardiac-infarct model (Bian et al., 2014).
Extracts of extracellular vesicles directly isolated from super-
natants of cardiac MSCs might be used to treat cardiac injuries
with even more promising results, although this topic awaits
investigation.
Based on the encouraging results of experimental studies,
a rapid transition from promising preclinical experiments to
early clinical trials occurred (Lovell and Mathur, 2011), although
numerous unresolved questions remain with respect to the
underlying molecular mechanisms involved in cell-based thera-
pies (Hoshino et al., 2007). Thus, cellular therapy has advanced
rapidly as a treatment option, with some concern within the
scientific community that this may have been occurring too
quickly and uncritically (Smith et al., 2008a). The nature of
this rapid transition meant that early studies considered the
safety and feasibility of cellular therapy and were of sufficient
power to assess its efficacy; however, these studies were sufficient
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to provoke early optimism in the medical community, even it
was based on the results of small studies (Lovell and Mathur,
2011).
Cellular Therapy with Cardiac Stem
Cells–Clinical Studies
The large body of preclinical evidence motivated human clini-
cal trials of CSCs (Bolli et al., 2011; Chugh et al., 2012). With
the primary goal of investigating the safety and feasibility of
using autologous CSCs for the treatment of heart failure result-
ing from ischemic heart disease, the SCIPIO (Stem Cell Infu-
sion in Patients with Ischemic cardiOmyopathy) study, the first
study of CSC treatment in humans, received approval to con-
duct a phase 1 clinical trial using CSCs (Chugh et al., 2012).
Methodologically, the investigators used autologous intracoro-
nary infusion of c-Kit+/Lin− CSCs derived from auricles that
were surgically harvested during coronary artery bypass graft
(CABG) in patients with ischemic cardiomyopathy. The LVEF
was improved by 8% at 4 months after stem-cell administration,
in contrast to no change in the control patients. However, the
phase I SCIPIO study was randomized and performed at a single
center, and autologous CSCs were administered to patients with
severe heart failure secondary to ischemic heart disease (Bolli
et al., 2011). In addition, the increase in ejection fraction (EF)
was even higher 1 year after the administration of CSCs, sug-
gesting that the CSCs continued to improve left ventricular (LV)
function over time, whereas the control group did not exhibit
improvement in the EF over time, ruling out any spontaneous
temporal benefit (Bolli et al., 2011). Furthermore, this improve-
ment in LV function was coupled with a concomitant decrease in
infarct size, which was consistently observed using three different
methods of cardiac magnetic resonance and was accompanied by
an increase in the LV viable mass, implying the robust regen-
eration of myocardial tissue (Chugh et al., 2012). The NYHA
functional classification also improved in the group that received
autologous CSC transplantation, as did their quality of life (Bolli
et al., 2011). Thus, the purpose of the SCIPIO study, to investigate
the safety of cellular administration, was achieved, and no adverse
effects attributable to CSC administration were noted (Bolli et al.,
2011), permitting the conclusion that the functional benefits of
CSCs were inversely related to the baseline functional status of
the myocardial region. That is, the lower the baseline function,
the greater the improvement afforded by CSC infusion (Chugh
et al., 2012). In addition to the safety of the procedure, this study
also demonstrated the feasibility of isolating and expanding CSCs
obtained from cardiac tissue during CABG surgery (Chugh et al.,
2012).
The CADUCEUS (CArdiosphere-Derived aUtologous stem
CElls to reverse ventricUlar dySfunction) clinical trial was
another prospective randomized trial of intracoronary infusions
of autologous CDCs in patients with recent myocardial infarc-
tion and residual systolic dysfunction. The phase 1 trial revealed
the feasibility and safety of this therapy, with no major adverse
cardiovascular events or cardiac tumor development (Makkar
et al., 2012). More importantly, CDCs treatment reduced the
extent of the scar mass and increased the level of regional
contractility observed at the 6-month follow-up but did not
improve the end-diastolic volume, end-systolic volume or the
LVEF (Makkar et al., 2012). The final results at the 1-year end-
point did not raise significant safety concerns and proved that,
despite improvements in the scar size and regional functionality
based on magnetic resonance imaging (MRI)-based analysis of
myocardial regeneration and clinical correlates of the regen-
erative efficacy, no improvements in global function, such as
improvements in the NYHA functional class, the peak VO2, the
distance walked in 6min or the quality of life after therapy using
CDCs, were detected (Malliaras et al., 2014). Covariate analysis
revealed that a higher baseline scar size was strongly associated
with a greater reduction in scar size 1 year after cellular infu-
sion (Malliaras et al., 2014). Importantly, a patient who under-
went late treatment and received the infused cells at 14 months
post-MI responded similarly to patients who were infused earlier
(at 1.5–3 months post-MI), indicating that CDCs administra-
tion might confer benefits to chronic ischemic cardiomyopathic
patients similar to those observed in convalescent MI patients
(Malliaras et al., 2014).
Another randomized, double-blind, placebo-controlled clini-
cal trial (phase I/II) that is still in progress is using, in contrast
to the CADUCEUS trial, allogeneic CDCs instead of autolo-
gous cells to achieve myocardial regeneration. The purpose of
the ALLSTAR study (ALLogeneic heart STem cells to achieve
myocArdial Regeneration) is to investigate the safety and effi-
cacy of the treatment in decreasing infarct size, with the primary
efficacy endpoint being the relative percentage improvement in
infarct size as assessed using magnetic resonance imaging at 6
and 12 months post-infusion (Allogeneic Heart Stem Cells to
Achieve Myocardial Regeneration (ALLSTAR) (NCT01458405)2.
More recently, a phase I/II randomized, double-blind, placebo
controlled clinical trial was proposed by a European study group
initiative (CARE-MI) to investigate the therapeutic role of allo-
geneic CSCs in patients with congestive heart failure due to
myocardial infarction (Crisostomo et al., 2015).
Despite the favorable results observed in some individu-
als treated with stem cells, certain clinical expectations were
not achieved because the levels of improvement in cardiac tis-
sue structure or functionality were less than those previously
observed in experimental and pre-clinical trials. Although several
challenges remain, such as optimization of the therapeutic proto-
cols and technological improvement of stem cell delivery devices,
it is believed that the current phase III studies will provide new
insights and accelerate the further development and acceptance
of cardiovascular regenerative medicine, particularly in relation
to reduced mortality following stem cell therapy and the optimal
sub selection of stem cells for clinical applications (Takashima
et al., 2013; Cheng et al., 2014).
Although clinical studies using stem cells obtained from dif-
ferent sources for cardiac-repair purposes have generally demon-
strated that CSC therapy is safe, it remains unclear why these
trials have failed to translate preclinical expectations in humans
2Available at: https://clinicaltrials.gov/ct2/show/study/NCT01458405 Accessed
January 10, 2015.
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(Lovell and Mathur, 2011). Various explanations for this discrep-
ancy have been suggested, such as the injection of an insufficient
number of cells or the wrong cell type, the use of an inap-
propriate delivery method, inappropriate timing relative to the
age of the infarct, and differences between animal models and
humans, including the absence of comorbidities in the animal
model (Lovell and Mathur, 2011) (Figure 3).
The results of both clinical and bench studies on this topic
demonstrate that there is much that remains to be investigated
in this field, particularly regarding the biodistribution of injected
cells, the optimal method and route for stem cell delivery, the
extent of cellular differentiation of these cells within the target
area (Hoshino et al., 2007) the precise paracrine signals that drive
the cell fate decision of multipotent progenitors, and the devel-
opment of novel approaches to deliver these signals in vivo (Lui
et al., 2013).
Cellular Therapy with Cardiac Stem
Cells–Future Directions
It may be relevant to investigate the effects of administering com-
binations of stem cells derived from different sources as alter-
native therapies and to determine the ideal number of these
cells to be used, the best timing of injection after damage has
occurred, the optimal frequency of injections, and the mecha-
nisms of action of the administered cells, as well as the extents of
their homing/grafting and survival and their preferential hom-
ing routes (Sánchez et al., 2010). However, many clinical trials
have demonstrated small improvements in FE that are sufficient
for substantial clinical improvement following stem cell admin-
istration, indicating the relevance of this strategy (Lovell and
Mathur, 2011). Based on these results, various alternatives are
being formulated (Smith et al., 2008a).
FIGURE 3 | Treatment using cardiac stem cells and associated
outcomes. Results support the feasibility and safety of the cardiac stem cell
delivery procedures, although the reports of outcomes have been limited and
primarily concerned to functional improvements or reductions in the infarct
size. Future studies will allow investigate other equally important outcomes,
such as improvements in the quality of life, maintaining the improvement in
ventricular function over time, and decreasing the mortality rate, among
others. However, there is still much to be explored in basic studies, which
may reveal the reasons why therapy using cardiac stem cells is not able to
heal the injured heart.
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In vitro studies have indicated the possibility of manipulat-
ing stem cells prior to transplantation to optimize their applica-
tion. For example, when c-kit+ CSCs exhibit an increased level of
expression of the transcription factor GATA4, their cardiosphere-
forming ability is reduced, indicating that their clonogenicity
and multipotentiality are also decreased, whereas, their ability to
differentiate into cardiomyocytes is increased (Miyamoto et al.,
2010). In vivo assays are required to confirm these conclusions.
Thus, uncertainties remain about the next steps to advance the
promising strategy of cellular therapy (Figure 3). Some have sug-
gested a return to the bench, whereas others support the continu-
ation of clinical practice because there are many examples of new
treatments that have been implemented with only a provisional
understanding of the underlying mechanisms, followed by elu-
cidation of the mechanisms with clinical experience (Lovell and
Mathur, 2011). Supporters of the continuity of clinical studies
base their opinions on the fact that, to date, the follow-up period
of subjects treated using CSCs is still short, and the vast major-
ity of outcomes investigated were cardiac functional parameters
or infarct size. Future studies may provide information about
the impact of cellular therapy on the long-term quality of life of
treated patients, the possible functional improvements that are
maintained over time and the reduction of the rate of or lack of
progression of heart failure or of the increase in the late mortality
rate following cardiac injury.
The electrophysiological properties of the in vivoCSC-derived
cardiomyocytes also remain to be investigated (Smith et al.,
2008a) because they were demonstrated to be as important
in tissue repopulation as the coupling of these newly formed
cells to the residual myocyte populations in the heart. The
functional integration of these cells was satisfactorily demon-
strated in a preclinical study that used an ex vivo prepa-
ration and two-photon microscopic analysis (Bearzi et al.,
2007), but the functional integration of these cells remains
to be demonstrated in clinical studies. Likewise, understand-
ing the physiology of the resident CSCs may lead to a better
understanding of how to expand and induce these cells to
differentiate into functional cardiomyocytes (Di Felice et al.,
2009) as well as vascular and endothelial cells within the
heart.
To summarize, the perspectives for future studies appear chal-
lenging yet encouraging; in particular, the interplay between basic
and clinical research will be critical for the development of the
field and for achievement of the final goal, which is a safe and
efficient therapy utilizing cardiac stem cells to regenerate lost
myocardium.
Conclusions
The currently available data encourage further investigation into
the potential application of cardiac multipotent cells to treat the
damaged heart. Although CSCs hold therapeutic promise for
clinical applicability, much remains to be explored.
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